Haemonetics (HAE) Director Michael J. Coyle Receives RSU Award

What Happened
Michael J. Coyle, a director of Haemonetics Corporation (HAE), received a grant of 2,538 restricted stock units (RSUs) on July 24, 2026. The filing lists the acquisition as an award (code A) with no purchase price (N/A). Each RSU represents a contingent right to one share of common stock when vested; the RSUs vest 100% on the first anniversary of the grant.

Key Details

• Transaction date: 2026-07-24 (Form 4 filed 2026-07-28; filing is within the SEC two-business-day window).
• Transaction type: Award/Grant (RSUs), 2,538 RSUs; price reported as N/A.
• Vesting: 100% vests on the first anniversary of the grant (per footnote).
• Each RSU = contingent right to one share on vesting.
• Shares owned after the transaction: not disclosed in the provided filing.
• No sale or open-market purchase occurred — this is a compensation award.

Context
RSU awards are typically compensation/retention tools and do not represent an immediate purchase or sale of stock. The RSUs will convert to actual shares only if and when they vest, at which point tax and reporting events may follow. This award alone does not necessarily indicate the director’s short-term market view.